Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2020 | ALS and FTD: current treatment landscape

Yuliya Shpilyukova • 17 May 2020
EAN 2020
Amyotrophic Lateral Sclerosis Dementia Edaravone Riluzole

Yuliya Shpilyukova, MD, Research Center of Neurology, Moscow, Russia, discusses the current treatment options for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Yuliya Shpilyukova

1:51
ALS and FTD future research
Yuliya Shpilyukova • 17 May 2020
2:31
C9orf72 hexanucleotide repeat expansion in ALS and FTD
Yuliya Shpilyukova • 17 May 2020

Related Videos

3:01
Results of pridopidine use in the Phase II HEALEY-ALS platform trial
Michael Hayden • 16 Apr 2024
4:49
Diagnostic utility of CSF biomarkers in patients with rapidly progressive dementia
Michael Geschwind • 23 Mar 2024
5:43
Introduction to rapidly progressive dementia: definitions and etiologies
Michael Geschwind • 23 Mar 2024
2:43
The key components of RPD assessment
Michael Geschwind • 23 Mar 2024
The content of VJNeurology is intended for healthcare professionals